{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T18:16:17Z","timestamp":1782756977928,"version":"3.54.5"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00280-025-04810-8","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T08:21:05Z","timestamp":1758010865000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical pharmacology and therapeutic applications of talazoparib: a comprehensive review"],"prefix":"10.1007","volume":"95","author":[{"given":"Saphal Lakshmi","family":"Pasupulati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katiboina","family":"Srinivasa Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushil","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Madhavrao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Rangari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arup Kumar","family":"Misra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. V. Simhachalam","family":"Kutikuppala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Devika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandhya Rani","family":"Sarikonda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,16]]},"reference":[{"issue":"6330","key":"4810_CR1","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1126\/science.aam7344","volume":"355","author":"CJ Lord","year":"2017","unstructured":"Lord CJ, Ashworth A (2017) PARP inhibitors: synthetic lethality in the clinic. Science 355(6330):1152\u20131158. https:\/\/doi.org\/10.1126\/science.aam7344","journal-title":"Science"},{"issue":"4","key":"4810_CR2","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1177\/10781552221073990","volume":"28","author":"RR George","year":"2022","unstructured":"George RR, Thomas R, Davice A, Mathew MS (2022) Veliparib for the treatment of solid malignancies. J Oncol Pharm Pract 28(4):924\u2013934. https:\/\/doi.org\/10.1177\/10781552221073990","journal-title":"J Oncol Pharm Pract"},{"key":"4810_CR3","doi-asserted-by":"publisher","unstructured":"Pham MM, Hinchcliff E, Avila M, Westin SN The clinical challenges, trials, and errors of combatting Poly(ADP-Ribose) polymerase inhibitors resistance. Cancer J 2021 Nov-Dec 01;27(6):491\u2013500. https:\/\/doi.org\/10.1097\/ppo.0000000000000562","DOI":"10.1097\/ppo.0000000000000562"},{"key":"4810_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40164-019-0154-9","volume":"8","author":"M Yi","year":"2019","unstructured":"Yi M, Dong B, Qin S, Chu Q, Wu K, Luo S (2019) Advances and perspectives of PARP inhibitors. Exp Hematol Oncol 8:29. https:\/\/doi.org\/10.1186\/s40164-019-0154-9","journal-title":"Exp Hematol Oncol"},{"issue":"3","key":"4810_CR5","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/oncolo\/oyab053","volume":"27","author":"MD Stewart","year":"2022","unstructured":"Stewart MD, Merino Vega D, Arend RC, Baden JF, Barbash O, Beaubier N et al (2022) Homologous recombination deficiency: concepts, definitions, and assays. Oncologist 27(3):167\u2013174. https:\/\/doi.org\/10.1093\/oncolo\/oyab053","journal-title":"Oncologist"},{"issue":"18","key":"4810_CR6","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1007\/s40265-018-1026-z","volume":"78","author":"SM Hoy","year":"2018","unstructured":"Hoy SM, Talazoparib (2018) First global approval. Drugs 78(18):1939\u20131946. https:\/\/doi.org\/10.1007\/s40265-018-1026-z","journal-title":"Drugs"},{"issue":"14","key":"4810_CR7","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1080\/14656566.2021.1952181","volume":"22","author":"EA Hobbs","year":"2021","unstructured":"Hobbs EA, Litton JK, Yap TA (2021) Development of the PARP inhibitor talazoparib for the treatment of advanced BRCA1 and BRCA2 mutated breast cancer. Expert Opin Pharmacother 22(14):1825\u20131837. https:\/\/doi.org\/10.1080\/14656566.2021.1952181","journal-title":"Expert Opin Pharmacother"},{"issue":"8","key":"4810_CR8","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/nejmoa1802905","volume":"379","author":"JK Litton","year":"2018","unstructured":"Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gon\u00e7alves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roch\u00e9 H, Im YH, Quek RGW, Markova D, Tudor IC, Hannah AL, Eiermann W, Blum JL (2018) Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med 379(8):753\u2013763. https:\/\/doi.org\/10.1056\/nejmoa1802905","journal-title":"N Engl J Med"},{"key":"4810_CR9","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/1477-7525-1-60","volume":"1","author":"CS Burckhardt","year":"2003","unstructured":"Burckhardt CS, Anderson KL (2003) The quality of life scale (QOLS): reliability, validity, and utilization. Health Qual Life Outcomes 1:60. https:\/\/doi.org\/10.1186\/1477-7525-1-60","journal-title":"Health Qual Life Outcomes"},{"key":"4810_CR10","unstructured":"National Center for Biotechnology Information PubChem Compound Summary for CID 135565082, Talazoparib. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Talazoparib. [Accessed Jan. 1, 2024.]"},{"issue":"12","key":"4810_CR11","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1007\/s40262-022-01167-6","volume":"61","author":"MAC Bruin","year":"2022","unstructured":"Bruin MAC, Sonke GS, Beijnen JH, Huitema ADR (2022) Pharmacokinetics and pharmacodynamics of PARP inhibitors in oncology. Clin Pharmacokinet 61(12):1649\u20131675. https:\/\/doi.org\/10.1007\/s40262-022-01167-6","journal-title":"Clin Pharmacokinet"},{"key":"4810_CR12","unstructured":"US FDA FDA-approved Drugs (Drugs Database). https:\/\/www.accessdata.fda.gov\/. Accessed [August 1st, 2025]"},{"issue":"2","key":"4810_CR13","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1002\/jcph.1520","volume":"60","author":"Y Yu","year":"2020","unstructured":"Yu Y, Durairaj C, Shi H, Wang DD (2020) Population pharmacokinetics of Talazoparib in patients with advanced cancer. J Clin Pharmacol 60(2):218\u2013228. https:\/\/doi.org\/10.1002\/jcph.1520","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"4810_CR14","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1111\/bcp.15294","volume":"88","author":"C Guo","year":"2022","unstructured":"Guo C, Yu Y, Chakrabarti J, Piha-Paul SA, Moroose R, Plotka A et al (2022) Evaluation of pharmacokinetics and safety of talazoparib in patients with advanced cancer and varying degrees of hepatic impairment. Br J Clin Pharmacol 88(7):3392\u20133403. https:\/\/doi.org\/10.1111\/bcp.15294","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"4810_CR15","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1002\/jcph.1415","volume":"59","author":"Y Yu","year":"2019","unstructured":"Yu Y, Chung CH, Plotka A, Quinn K, Shi H, P\u00e1pai Z, Nguyen L, Wang D (2019) A phase 1 mass balance study of 14\u00a0C\u2013Labeled talazoparib in patients with advanced solid tumors. J Clin Pharmacol 59(9):1195\u20131203. https:\/\/doi.org\/10.1002\/jcph.1415","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"4810_CR16","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s40262-020-00983-y","volume":"60","author":"C Durairaj","year":"2021","unstructured":"Durairaj C, Chakrabarti J, Ferrario C, Hirte HW, Babu S, Piha-Paul SA, Plotka A, Hoffman J, Shi H, Wang DD (2021) The effect of renal impairment on the pharmacokinetics and safety of Talazoparib in patients with advanced solid tumors. Clin Pharmacokinet 60(7):921\u2013930. https:\/\/doi.org\/10.1007\/s40262-020-00983-y","journal-title":"Clin Pharmacokinet"},{"key":"4810_CR17","unstructured":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD) National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Talazoparib. [Updated 2019 Jan 20]. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548621\/. [Accessed August 1st,2025]"},{"issue":"2","key":"4810_CR18","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s40268-020-00301-8","volume":"20","author":"S Boussios","year":"2020","unstructured":"Boussios S, Abson C, Moschetta M, Rassy E, Karathanasi A et al (2020) Poly (ADP-ribose) polymerase inhibitors: talazoparib in ovarian cancer and beyond. Drugs R D 20(2):55\u201373. https:\/\/doi.org\/10.1007\/s40268-020-00301-8","journal-title":"Drugs R D"},{"issue":"2","key":"4810_CR19","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3390\/cells8020195","volume":"8","author":"T Mukai","year":"2019","unstructured":"Mukai T, Fujita S, Morita Y (2019) Tankyrase (PARP5) inhibition induces bone loss through accumulation of its substrate SH3BP2. Cells 8(2):195. https:\/\/doi.org\/10.3390\/cells8020195","journal-title":"Cells"},{"key":"4810_CR20","unstructured":"US FDA FDA approves talazoparib for gBRCAm HER2-negative locally advanced or metastatic breast cancer [Internet]. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-talazoparib-gbrcam-her2-negative-locally-advanced-or-metastatic-breast-cancer. [ Accessed Aug 1st, 2025]"},{"key":"4810_CR21","unstructured":"ClinicalTrials.gov National Library of Medicine. https:\/\/www.clinicaltrials.gov\/. [Accessed August 1st, 2025]"},{"issue":"9","key":"4810_CR22","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1158\/1078-0432.ccr-18-1891","volume":"25","author":"NC Turner","year":"2019","unstructured":"Turner NC, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke EM, ABRAZO Study Group et al (2019) A phase II study of talazoparib after platinum or cytotoxic nonplatinum regimens in patients with advanced breast cancer and germline BRCA1\/2 mutations (ABRAZO). Clin Cancer Res 25(9):2717\u20132724. https:\/\/doi.org\/10.1158\/1078-0432.ccr-18-1891","journal-title":"Clin Cancer Res"},{"issue":"11","key":"4810_CR23","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1016\/j.annonc.2020.08.2098","volume":"31","author":"JK Litton","year":"2020","unstructured":"Litton JK, Hurvitz SA, Mina LA, Rugo HS, Lee KH, Gon\u00e7alves A, Diab S, Woodward N, Goodwin A, Yerushalmi R, Roch\u00e9 H, Im YH, Eiermann W, Quek RGW, Usari T, Lanzalone S, Czibere A, Blum JL, Martin M, Ettl J (2020) Talazoparib versus chemotherapy in patients with germline BRCA1\/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol 31(11):1526\u20131535. https:\/\/doi.org\/10.1016\/j.annonc.2020.08.2098","journal-title":"Ann Oncol"},{"issue":"5","key":"4810_CR24","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1200\/jco.19.01304","volume":"38","author":"JK Litton","year":"2020","unstructured":"Litton JK, Scoggins ME, Hess KR, Adrada BE, Murthy RK, Damodaran S et al (2020) Neoadjuvant talazoparib for patients with operable breast cancer with a germline BRCA pathogenic variant. J Clin Oncol 38(5):388\u2013394. https:\/\/doi.org\/10.1200\/jco.19.01304","journal-title":"J Clin Oncol"},{"issue":"5","key":"4810_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/jbt.22286","volume":"33","author":"G Guney Eskiler","year":"2019","unstructured":"Guney Eskiler G, Cecener G, Egeli U, Tunca B (2019) BMN 673 (talazoparib): a potent PARP inhibitor for triple negative breast cancer with different genetic profile. J Biochem Mol Toxicol 33(5):e22286. https:\/\/doi.org\/10.1002\/jbt.22286","journal-title":"J Biochem Mol Toxicol"},{"issue":"4","key":"4810_CR26","doi-asserted-by":"publisher","first-page":"425","DOI":"10.2217\/fon-2021-0811","volume":"18","author":"N Agarwal","year":"2022","unstructured":"Agarwal N, Azad A, Shore ND, Carles J, Fay AP, Dunshee C et al (2022) Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design. Future Oncol 18(4):425\u2013436. https:\/\/doi.org\/10.2217\/fon-2021-0811","journal-title":"Future Oncol"},{"issue":"10","key":"4810_CR27","doi-asserted-by":"publisher","first-page":"e783","DOI":"10.1093\/oncolo\/oyac172","volume":"27","author":"N Mehra","year":"2022","unstructured":"Mehra N, Fizazi K, de Bono JS, Barth\u00e9l\u00e9my P, Dorff T, Stirling A et al (2022) Talazoparib, a Poly(ADP-ribose) polymerase inhibitor, for metastatic Castration-resistant prostate cancer and DNA damage response alterations: TALAPRO-1 safety analyses. Oncologist 27(10):e783\u2013e795. https:\/\/doi.org\/10.1093\/oncolo\/oyac172","journal-title":"Oncologist"},{"issue":"1","key":"4810_CR28","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41591-023-02704-x","volume":"30","author":"K Fizazi","year":"2024","unstructured":"Fizazi K, Azad AA, Matsubara N, Carles J, Fay AP, De Giorgi U et al (2024) First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nat Med 30(1):257\u2013264. https:\/\/doi.org\/10.1038\/s41591-023-02704-x","journal-title":"Nat Med"},{"issue":"4","key":"4810_CR29","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.eururo.2022.05.030","volume":"83","author":"F Saad","year":"2023","unstructured":"Saad F, de Bono J, Barth\u00e9l\u00e9my P, Dorff T, Mehra N, Scagliotti G et al (2023) Patient-reported outcomes in men with metastatic Castration-resistant prostate cancer harboring DNA damage response alterations treated with talazoparib: results from TALAPRO-1. Eur Urol 83(4):352\u2013360. https:\/\/doi.org\/10.1016\/j.eururo.2022.05.030","journal-title":"Eur Urol"},{"issue":"6","key":"4810_CR30","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1158\/2159-8290.cd-16-1250","volume":"7","author":"J de Bono","year":"2017","unstructured":"de Bono J, Ramanathan RK, Mina L, Chugh R, Glaspy J, Rafii S et al (2017) Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1\/2 mutations and selected sporadic cancers. Cancer Discov 7(6):620\u2013629. https:\/\/doi.org\/10.1158\/2159-8290.cd-16-1250","journal-title":"Cancer Discov"},{"key":"4810_CR31","doi-asserted-by":"publisher","first-page":"6400","DOI":"10.1158\/1078-0432.ccr-17-0703","volume":"23","author":"MS Dhawan","year":"2017","unstructured":"Dhawan MS, Bartelink IH, Aggarwal RR, Leng J, Zhang JZ, Pawlowska N et al (2017) Differential toxicity in patients with and without DNA repair mutations: phase I study of carboplatin and talazoparib in advanced solid tumors. Clin Cancer Res 23:6400\u20136410. https:\/\/doi.org\/10.1158\/1078-0432.ccr-17-0703","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4810_CR32","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1038\/s41598-018-22022-4","volume":"8","author":"P Lesueur","year":"2018","unstructured":"Lesueur P, Chevalier F, El-Habr EA, Junier MP, Chneiweiss H, Castera L et al (2018) Radiosensitization effect of talazoparib, a PARP inhibitor, on glioblastoma stem cells exposed to low and high linear energy transfer radiation. Sci Rep 8(1):3664. https:\/\/doi.org\/10.1038\/s41598-018-22022-4","journal-title":"Sci Rep"},{"issue":"12","key":"4810_CR33","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1158\/1535-7163.mct-17-0365","volume":"16","author":"SH Kizilbash","year":"2017","unstructured":"Kizilbash SH, Gupta SK, Chang K, Kawashima R, Parrish KE, Carlson BL et al (2017) Restricted delivery of Talazoparib across the blood\u2013brain barrier limits the sensitizing effects of PARP inhibition on Temozolomide therapy in glioblastoma. Mol Cancer Ther 16(12):2735\u20132746. https:\/\/doi.org\/10.1158\/1535-7163.mct-17-0365","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"4810_CR34","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1158\/1078-0432.ccr-19-2549","volume":"26","author":"S Wu","year":"2020","unstructured":"Wu S, Gao F, Zheng S, Zhang C, Martinez-Ledesma E, Ezhilarasan R et al (2020) EGFR amplification induces increased DNA damage response and renders selective sensitivity to Talazoparib (PARP inhibitor) in glioblastoma. Clin Cancer Res 26(6):1395\u20131407. https:\/\/doi.org\/10.1158\/1078-0432.ccr-19-2549","journal-title":"Clin Cancer Res"},{"key":"4810_CR35","doi-asserted-by":"publisher","unstructured":"Kohl V, Flach J, Naumann N, Brendel S, Kleiner H, Weiss C et al (2019) Antileukemic efficacy in vitro of Talazoparib and APE1 inhibitor III combined with decitabine in myeloid malignancies. Cancers (Basel). 11(10):1493. https:\/\/doi.org\/10.3390\/cancers11101493","DOI":"10.3390\/cancers11101493"},{"issue":"1","key":"4810_CR36","doi-asserted-by":"publisher","first-page":"4435","DOI":"10.1182\/blood-2021-151636","volume":"138","author":"M Swaminathan","year":"2021","unstructured":"Swaminathan M, Przespolewski A, Griffiths EA, Thompson JE, Elshoury A, Walinski W et al (2021) Phase 1b trial of Talazoparib and Gemtuzumab Ozogamicin in adult patients with CD33\u2009+\u2009relapsed or refractory acute myeloid leukemia. Blood 138(1):4435","journal-title":"Blood"},{"issue":"7","key":"4810_CR37","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1158\/1078-0432.ccr-21-3729","volume":"28","author":"MR Baer","year":"2022","unstructured":"Baer MR, Kogan AA, Bentzen SM, Mi T, Lapidus RG, Duong VH et al (2022) Phase I clinical trial of DNA methyltransferase inhibitor decitabine and PARP inhibitor talazoparib combination therapy in relapsed\/refractory acute myeloid leukemia. Clin Cancer Res 28(7):1313\u20131322. https:\/\/doi.org\/10.1158\/1078-0432.ccr-21-3729","journal-title":"Clin Cancer Res"},{"issue":"20","key":"4810_CR38","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1158\/1078-0432.ccr-18-0401","volume":"24","author":"JH Laird","year":"2018","unstructured":"Laird JH, Lok BH, Ma J, Bell A, de Stanchina E et al (2018) Talazoparib is a potent radiosensitizer in small cell lung cancer cell lines and xenografts. Clin Cancer Res 24(20):5143\u20135152. https:\/\/doi.org\/10.1158\/1078-0432.ccr-18-0401","journal-title":"Clin Cancer Res"},{"issue":"9","key":"4810_CR39","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1016\/j.jtho.2022.07.060","volume":"17","author":"J Goldman","year":"2022","unstructured":"Goldman J, Cummings A, Mendenhall M, Velez MA, Babu S, Johnson T et al (2022) OA12.03 Phase 2 Study Analysis of Talazoparib (TALA) Plus Temozolomide (TMZ) for Extensive-Stage Small Cell Lung Cancer (ES-SCLC). J Thorac Oncol 17(9):S32","journal-title":"J Thorac Oncol"},{"issue":"30","key":"4810_CR40","doi-asserted-by":"publisher","first-page":"48794","DOI":"10.18632\/oncotarget.10720","volume":"8","author":"F Engert","year":"2017","unstructured":"Engert F, Kovac M, Baumhoer D, Nathrath M, Fulda S (2017) Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics. Oncotarget 8(30):48794\u201348806. https:\/\/doi.org\/10.18632\/oncotarget.10720","journal-title":"Oncotarget"},{"key":"4810_CR41","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.3389\/fonc.2019.01416","volume":"9","author":"P Baldwin","year":"2019","unstructured":"Baldwin P, Likhotvorik R, Baig N, Cropper J, Carlson R, Kurmasheva R et al (2019) Nanoformulation of Talazoparib increases maximum tolerated doses in combination with Temozolomide for treatment of ewing sarcoma. Front Oncol 9:1416. https:\/\/doi.org\/10.3389\/fonc.2019.01416","journal-title":"Front Oncol"},{"issue":"2","key":"4810_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28073","volume":"67","author":"ES Schafer","year":"2020","unstructured":"Schafer ES, Rau RE, Berg SL, Liu X, Minard CG, Bishop AJR et al (2020) Phase 1\/2 trial of Talazoparib in combination with Temozolomide in children and adolescents with refractory\/recurrent solid tumors including Ewing sarcoma: a children\u2019s oncology group phase 1 consortium study (ADVL1411). Pediatr Blood Cancer 67(2):e28073. https:\/\/doi.org\/10.1002\/pbc.28073","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"4810_CR43","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/j.annonc.2020.08.2265","volume":"31","author":"PA Konstantinopoulos","year":"2020","unstructured":"Konstantinopoulos PA, Gockley AA, Xiong N, Tayob N, Krasner CN, Buss M et al (2020) Phase II study of PARP inhibitor Talazoparib and PD-L1 inhibitor avelumab in patients (pts) with microsatellite stable (MSS) recurrent\/persistent endometrial cancer. Ann Oncol 31(4):1165","journal-title":"Ann Oncol"},{"issue":"3","key":"4810_CR44","first-page":"10","volume":"42","author":"KJ Yost","year":"2024","unstructured":"Yost KJ, Rothe M, Mangat PK, Garrett-Mayer E, Duvivier HL, Ahn ER et al (2024) Talazoparib (Tala) in patients (pts) with colorectal cancer (CRC) with BRCA1\/2 mutations (mut): results from the targeted agent and profiling utilization registry (TAPUR) study. J Clin Oncol 42(3):10","journal-title":"J Clin Oncol"},{"key":"4810_CR45","doi-asserted-by":"publisher","unstructured":"Hage Chehade C, Gebrael G, Sayegh N, Ozay ZI, Narang A, Crispino T, Golan T, Litton JK, Swami U, Moore KN, Agarwal N (2025 Mar-Apr) A pan-tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors. CA Cancer J Clin 75(2):141\u2013167. https:\/\/doi.org\/10.3322\/caac.21870","DOI":"10.3322\/caac.21870"},{"issue":"1\u20132","key":"4810_CR46","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1053\/j.seminoncol.2023.09.005","volume":"51","author":"Y Zeng","year":"2024","unstructured":"Zeng Y, Arisa O, Peer CJ, Fojo A, Figg WD (2024) PARP inhibitors: a review of the pharmacology, pharmacokinetics, and pharmacogenetics. Semin Oncol 51(1\u20132):19\u201324. https:\/\/doi.org\/10.1053\/j.seminoncol.2023.09.005","journal-title":"Semin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04810-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-025-04810-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04810-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T21:03:51Z","timestamp":1758056631000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-025-04810-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,16]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4810"],"URL":"https:\/\/doi.org\/10.1007\/s00280-025-04810-8","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,16]]},"assertion":[{"value":"19 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"87"}}